DCM
IRON icon

DAFNA Capital Management’s Disc Medicine IRON Stock Holding History

DAFNA Capital Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,000
Closed -$2.03M – 87
2021
Q1 		$2.03M Buy
+5,000
New +$2.23M 0.48% 49

Other funds holding IRON

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

DAFNA Capital Management's IRON Position: Q2 2021 in Review

DAFNA Capital Management sold out of Disc Medicine (IRON) in Q2 2021, closing a stake of 5,000 shares — an estimated $2.03M sold.

DAFNA Capital Management first reported a position in IRON in Q1 2021 and held it in 1 quarter. The position peaked at $2.03M in Q1 2021. 55 funds tracked by Wall St. Rank hold IRON as of Q2 2021.

  • DAFNA Capital Management reported no remaining Disc Medicine position as of Q2 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 5,000 Disc Medicine shares in Q2 2021, an estimated $2.03M.
  • DAFNA Capital Management first reported a position in Disc Medicine in Q1 2021 and held it in 1 quarter.
  • DAFNA Capital Management's Disc Medicine position peaked at $2.03M in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2021.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.